Fluorouracil for injection

This product is first converted into 5-fluoro-2-deoxyuridine nucleotide in the body, which inhibits thymine nucleotide synthetase, blocking the conversion of deoxyuridine nucleotide into deoxythymine nucleotide, thereby inhibiting DNA biosynthesis. In addition, by preventing uracil and orotic acid from incorporating into RNA, the effect of inhibiting RNA synthesis is achieved. This product is a cell cycle-specific drug that mainly inhibits S-phase cells.

Fluorouracil

1. This product can be used for adjuvant and palliative treatment of breast cancer, digestive tract cancer (including primary and metastatic liver cancer, biliary system tumors and pancreatic cancer), ovarian cancer and primary bronchopulmonary adenocarcinoma; 2. It can be used to treat malignant hydatidiform mole and choriocarcinoma; 3. It can be used for intensive intra-arterial chemotherapy of serous cavity cancerous effusion and bladder cancer; 4. It can be used for intra-arterial catheter chemotherapy of head and neck malignant tumors and liver cancer.

The dosage of fluorouracil for intravenous injection or intravenous drip varies greatly. The single-drug intravenous injection dose is generally 10-20 mg/kg per day based on body weight, used for 5-10 days, and 5-7 grams (or even 10 grams) per course of treatment. If it is intravenous drip, it is usually 300-500 mg/m2 per day based on body surface area, used for 3-5 days, and each intravenous drip time must not be less than 6-8 hours; during intravenous drip, an infusion pump can be used to continuously administer the drug for 24 hours. For primary or metastatic liver cancer, arterial catheterization is often used for injection. Intraperitoneal injection is 500-600 mg/m2 per body surface area. Once a week, 2-4 times as a course of treatment.

1. Nausea, loss of appetite or vomiting. Generally, the dose is not serious. Occasionally, oral mucosal inflammation or ulcers, abdominal discomfort or diarrhea are seen. Peripheral blood leukopenia is common (mostly reaches the lowest point within 2 to 3 weeks after the start of the treatment, and returns to normal after about 3 to 4 weeks), and thrombocytopenia is rare. Cough, shortness of breath or cerebellar ataxia are extremely rare. 2. Long-term use may lead to nervous system toxicity. 3. Occasionally, myocardial ischemia occurs after medication, and angina pectoris and electrocardiogram changes may occur. If cardiovascular adverse reactions (arrhythmia, angina pectoris, ST segment changes) are confirmed, discontinue use.

A very small number of human cases have been diagnosed with congenital malformations due to the use of this drug within the first three months of pregnancy, and this may have long-term effects on the fetus. Therefore, this drug is contraindicated in women within the first three months of pregnancy. Due to the potential mutagenicity, teratogenicity and carcinogenicity of this drug and the possible toxic and side effects in infants, breastfeeding is not allowed during the use of this drug. This drug is contraindicated when accompanied by varicella or herpes zoster. Fluorouracil is contraindicated for use in debilitated patients.

It has been reported that a variety of drugs can biochemically affect the anti-cancer effect or toxicity of fluorouracil, common drugs include methotrexate, metronidazole and tetrahydrofolate. When used in combination with methotrexate, methotrexate should be given 4 to 6 hours before fluorouracil, otherwise the effect will be reduced. Giving tetrahydrofolate first and then fluorouracil can increase its efficacy. This product can generate a neurotoxic metabolite - fluorocitric acid, which can cause cerebral palsy, so it cannot be injected intrathecally. Allopurinol can reduce the bone marrow suppression caused by fluorouracil.

Keep away from light and store in a sealed container.

0.25g

Yuanda Pharmaceutical Huangshi Feiyun Pharmaceutical Co., Ltd.

• Founded in:

  2013-02-22

• Address:

  No. 69, Jinshan Avenue East, Huangshi City

• Tax NO.:

  91420200060689700K

• Registered Funds:

  125 million yuan

• Website:

  Log in to view

• Email:

  Log in to view